<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">273</article-id><article-id pub-id-type="doi">10.25208/0042-4609-2016-92-5-72-78</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DRUG TREATMENT IN DERMATOVENEROLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Strategy for managing patients with severe cases of rosacea</article-title><trans-title-group xml:lang="ru"><trans-title>Тактика ведения пациентов с тяжелым розацеа</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sergeyeva</surname><given-names>I. G.</given-names></name><name xml:lang="ru"><surname>Сергеева</surname><given-names>И. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>i_g_sergeeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Krinitsyna</surname><given-names>Yu. M.</given-names></name><name xml:lang="ru"><surname>Криницына</surname><given-names>Ю. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Novosibirsk State National Research University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Institute of regional Pathology and Pathomorphology</institution></aff><aff><institution xml:lang="ru">ФГБ НУ «Институт молекулярной патологии и патоморфологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-10-24" publication-format="electronic"><day>24</day><month>10</month><year>2016</year></pub-date><volume>92</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>72</fpage><lpage>78</lpage><history><date date-type="received" iso-8601-date="2017-08-24"><day>24</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Sergeyeva I.G., Krinitsyna Y.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Сергеева И.Г., Криницына Ю.М.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Sergeyeva I.G., Krinitsyna Y.M.</copyright-holder><copyright-holder xml:lang="ru">Сергеева И.Г., Криницына Ю.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/273">https://vestnikdv.ru/jour/article/view/273</self-uri><abstract xml:lang="en"><p>The article presents 3 clinical observations of women of 51, 55 and 57 years old with severe rosacea, who reached the state of remission after a prolonged course of systemic therapy with low doses of isotretinoin. Cumulative dose of isotretinoin for persistent clinical remission was 46.4 mg/kg of weight, 17.6 mg/kg, 12.6 mg/kg respectively. Difficulties related to the subjective perception of patients of his condition has limited the possibility of increasing daily dose of isotretinoin, and the lack of result from the previous therapy with basic medications has made isotretinoin a drug of choice.</p></abstract><trans-abstract xml:lang="ru"><p>В статье приводится 3 клинических наблюдения женщин 51, 55 и 57 лет с тяжелым течением розацеа, достигших состояния ремиссии после длительного курса системной терапии низкими дозами изотретиноина. Кумулятивная доза изотретиноина до достижения стойкой клинической ремиссии составила 46,4 мг/кг веса, 17,6 мг/кг веса, 12,6 мг/кг веса соответственно. Общая продолжительность курса лечения 16, 15 и 13 мес. Сложности, связанные с субъективным восприятием пациентками своего состояния, ограничивали возможность увеличения суточной дозы изотретиноина, а отсутствие эффекта от предшествующей терапии базовыми препаратами делало изотретиноин препаратом выбора.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>розацеа</kwd><kwd>изотретиноин в форме LIDOSE</kwd><kwd>rosacea</kwd><kwd>isotretinoin in the form of LIDOSE</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Araviyskaya E.R.. Samtsov A.V. Federalnyye klinicheskiye rekomendatsii po vedeniyu bolnykh rozatsea. Moskva; 2015</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Rademaker M. Very low-dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients. The Australasian Journal Of Dermatology 2016; 20: 1440-0960.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sbidian E., Vicaut É., Chosidow O. et al. A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea. The Journal Of Investigative Dermatology 2016; 136 (6): 1124-1129.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed 2003; 2: 43-47.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Egeberg A., Hansen P., Gislason G., Thyssen J. Patients with Rosacea Have Increased Risk of Depression and Anxiety Disorders: A Danish Nationwide Cohort Study. Dermatology 2016; 232 (2): 208-213.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Monakhov S.A. Rozatsea (metodicheskoye posobiye dlya vrachey). M; 2016.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Samtsov A.V. Gorbunov Yu.G. Izotretinoin v lechenii rozatsea. Vestn dermatol venerol 2012; (4): 102-104</mixed-citation></ref></ref-list></back></article>
